Cefpodoxime proxetil as a therapeutic option in switching therapy for infective endocarditis in children: case reports and literature review. (18th August 2019)

• Record Type: Journal Article
• Authors: Krajcar, Nina; Marić, Lorna Stemberger; Šarić, Dalibor; Milić, Neven; Tešović, Goran
• Is Part Of: Journal of chemotherapy. Volume 31:Number 6(2019)
• Page Start: 354
• Page End: 358
• Publication Date: 2019-08-18
• Subjects: Cefpodoxime proxetil -- infective endocarditis -- oral therapy -- children -- Abiotrophia defectiva -- Haemophilus parainfluenzae; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2019.1603797
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Infective endocarditis (IE) is uncommon in children, affecting predominantly subjects with congenital heart disease (CHD) and patients with indwelling central lines. The principles of antibiotic treatment in paediatric population are similar to those in adults. Prolonged intravenous administration of bactericidal rather than bacteriostatic agents is preferred. Outpatient intravenous therapy after initial treatment in the hospital may be considered only in selected patients. Partial oral treatment has been described in cases of left-sided, uncomplicated IE caused by common pathogens in adult patients. There are no guidelines or trials in paediatric population regarding switching therapy from intravenous to oral route. We present two cases of IE in children caused by uncommon pathogenic bacteria ( Abiotrophia defectiva and Haemophilus parainfluenzae ) successfully treated with oral third-generation cephalosporin – cefpodoxime proxetil after initial intravenous therapy. This paper provides observations on different therapeutic approach for IE in children as well as another potential use of cefpodoxime proxetil.